Verona Pharma plc
VRNA
Rank in Stocks
#2230
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Share Price
$106.91
Last synced: 2025-10-07
Market Cap
$9.09B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
GB
Trade Verona Pharma plc (VRNA)
Category
Healthcare
Earnings for Verona Pharma plc (VRNA)
Earnings in Jun 2025 TTM: $-56.52M
According to Verona Pharma plc latest financial reports the company's current earnings are $-56.52M. In 2023 the company made an earning of $-42.28M, an increase over its 2022 earnings that were of $-56.62M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Verona Pharma plc from 2005 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-56.52M | -56.62% |
| 2024 | $-130.30M | 208.20% |
| 2023 | $-42.28M | -25.33% |
| 2022 | $-56.62M | 37.75% |
| 2021 | $-41.10M | -13.52% |
| 2020 | $-47.53M | 17.27% |
| 2019 | $-40.53M | 31.86% |
| 2018 | $-30.74M | -9.75% |
| 2017 | $-34.06M | 362.02% |
| 2016 | $-7.37M | -44.44% |
| 2015 | $-13.27M | 126.33% |
| 2014 | $-5.86M | 25.78% |
| 2013 | $-4.66M | 75.08% |
| 2012 | $-2.66M | -40.09% |
| 2011 | $-4.44M | -2.04% |
| 2010 | $-4.54M | 8.38% |
| 2009 | $-4.18M | 45.74% |
| 2008 | $-2.87M | -40.29% |
| 2007 | $-4.81M | 105.89% |
| 2006 | $-2.34M | -3,133.92% |
| 2005 | $76.99K | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -9,432.91% |
US
|
|
| $-3.09B | 5,361.85% |
US
|
|
| $-4.02B | 7,005.88% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,551.30% |
NL
|
